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The CCL3 Family of Chemokines and Innate Immunity
Cooperate In Vivo in the Eradication of an Established
Lymphoma Xenograft by Rituximab1
Elena Cittera,*† Marzia Leidi,* Chiara Buracchi,‡ Fabio Pasqualini,‡ Silvano Sozzani,§
Annunciata Vecchi,‡ J. Douglas Waterfield,¶ Martino Introna,* and Jose´e Golay2*
The therapeutic mAb rituximab induced the expression of the CCL3 and CCL4 chemokines in the human lymphoma line BJAB
following binding to the CD20 Ag. Induction of CCL3/4 in vitro was specific, was observed in several cell lines and freshly isolated
lymphoma samples and also took place at the protein level in vitro and in vivo. To investigate the role of these -chemokines in
the mechanism of action of rituximab, we synthesized a N-terminally truncated CCL3 molecule CCL3(11–70), which had antag-
onist activity on chemotaxis mediated by either CCL3 or BJAB supernatant. We also set up an established s.c. BJAB tumor model
in athymic mice. Rituximab, given weekly after tumors had reached 250 mm2, led to complete disappearance of the lymphoma
within 2–3 wk. Treatment of mice with cobra venom factor showed that complement was required for rituximab therapeutic
activity. Treatment of BJAB tumor bearing mice every 2 days with the CCL3(11–70) antagonist, starting 1 wk before rituximab
treatment, had no effect on tumor growth by itself, but completely inhibited the therapeutic activity of the Ab. To determine
whether CCL3 acts through recruitment/activation of immune cells, we specifically depleted NK cells, polymorphonuclear cells,
and macrophages using mAbs, clodronate treatment, or Rag2/c/ mice. The data demonstrated that these different cell
populations are involved in BJAB tumor eradication. We propose that rituximab rapidly activates complement and induces
-chemokines in vivo, which in turn activate the innate immunity network required for efficient eradication of the bulky BJAB
tumor. The Journal of Immunology, 2007, 178: 6616–6623.
T he chimeric unconjugated monoclonal IgG1 Ab rituximab(Mabthera, Rituxan) is approved for the treatment of low-or high-grade non-Hodgkin’s B lymphoma and is shown
in therapeutic activity in other B cell neoplasms such as B cell
lymphocytic leukemia and diffuse large B cell lymphoma (1–5).
Although rituximab has shown clear clinical activity in different
non-Hodgkin’s B lymphoma subtypes in phase III trials, identify-
ing the factors that determine the clinical response and the efficacy
of the Ab is still a major challenge. The mechanism of action of
rituximab in vivo is thought to depend mostly upon immune-me-
diated mechanisms, but the relative contribution of different effec-
tor mechanisms is a matter of large debate (6). Different animal
models of lymphoma have been described that have emphasized a
role for either Ab-dependent cytotoxicity by NK cells and neutro-
phils (7, 8) or for phagocytosis mediated by the monocyte network
(9, 10) or by complement activation (11–13). These mechanisms,
however, are likely to be linked to each other. For example the
complement cascade may cause direct target cell lysis by the mem-
brane attack complex as well as induce recruitment and activation
of different immune effector cells after activation and release of
potent anaphylatoxins like C5a and C3a (14, 15). Finally, the role
of different mechanisms is likely to vary in different tumor types or
localizations (10).
Rituximab binding to the CD20 molecule also activates re-
stricted intracellular signaling pathways. Recently we have inves-
tigated these direct effects of rituximab on lymphoma cells using a
gene chip screening approach (16) and found several genes in-
duced by the Ab in different lymphoma cells. Two of the genes of
biological interest were CCL3 (Mip1-) and CCL4 (Mip1-),
which were up-regulated in BJAB lymphoma cells in vitro after
stimulation with rituximab. CCL3 and CCL4 belong to the family
of  (CC) chemokines expressed generally in a coordinated fash-
ion by a number of cell types, including activated B cells, mono-
cytes, mast cells, fibroblasts, and epithelial cells (17). They are
highly conserved between mouse and human models (18) and both
signal through the CCR1 and CCR5 receptors. These receptors are
also shared by other -chemokine family members such as CCL5
(RANTES). CCL3 and CCL4 induce the infiltration of neutrophils,
macrophages, NK cells, and T cells in tumors. CCL3 has been
implicated in antitumor activity in several mouse models of solid
tumors (19–23). In addition CCL3 has the capacity to activate
certain cell types (20, 24), to affect proliferation of hemopoietic
cells (25, 26), and has osteoclastic properties in vitro or in vivo
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(27). Furthermore, CCL3 plays an important role in different mod-
els of inflammation in vivo (28–30). Given the important biolog-
ical activities of CCL3/4, we have investigated whether rituximab
induces these proteins in vitro and in vivo and whether these che-
mokines played a role in the therapeutic activity of rituximab in a
xenograft model of lymphoma.
Materials and Methods
Cells and Abs
The human Burkitt’s lymphoma cell line BJAB (31) was cultured in RPMI
1640 medium (Seromed) supplemented with 10% FCS (HyClone Labora-
tories), 2 mM glutamine (Invitrogen Life Technologies), and 100 IU/ml
penicillin/streptomycin. Bone marrow mononuclear cells from two Burkitt’s
lymphoma patients (pt1 and pt2) and one ALL-L3 patient (pt3) were
separated on a Ficoll-Hypaque density gradient. Neoplastic cells in these
samples were 85–99%. Rituximab was a gift of Roche Italia. Alemtuzumab
(Campath-1H) was donated by Schering-Plough (Kenilworth, NJ). The
humanized anti-CD25 Ab daclizumab (Zenapax; Roche) was provided
by Dr. A. Rambaldi (Ospedali Riuniti, Bergamo, Italy). The purified
Abs HD239 (CD22), HD50 (CD23), and HD28 (CD37) were a gift from
Dr. G. Moldenhauer (DKFZ, Heidelberg, Germany) and stained BJAB
cells positively. Purified rituximab F(ab)2 was a gift from Prof. E. S.
Vitetta (University of Texas, Dallas, TX).
Real-time PCR
Total RNA was extracted in guanidinium isocyanate and purified by stan-
dard cesium chloride gradient centrifugation. CCL3 and CCL4 gene ex-
pression was quantified in reverse transcription RNA by real-time PCR
using the SYBR Green Master Mix (Applied Biosystems) and 300 nM each
of oligonucleotide and normalization against -actin, as previously de-
scribed (16). The oligonucleotides were as follows: CCL3 5-ACTACTT
TGAGACGAGCAGCCAG and 5-GCCGGCTTCGCTTGGT; CCL4 5-
CTCTCAGCACCAATGGGCTC and 5-GTAAGAAAAGCAGCAGGC
GG; and -actin 5-CCCAAGGCCAACCGCGAGAAGAT and 5-GT
CCCGGCCAGCCAGGTCCAG.
Tumor model
The therapeutic effect of rituximab was tested in all cases on established
tumor and was analyzed as follows. Five-week-old male CD-1 nu/nuBR
mice (Charles River Breeding Laboratories) were used. Groups of 3.0 Gy
irradiated animals were s.c. inoculated with 10  106 BJAB cells in each
flank, and tumor growth was measured twice weekly. When the tumor
reached 250 mm2 (within 3–4 wk, but defined as day 0 with respect to
rituximab treatment for uniformity), the mice were i.p. treated once a week
with 250 g of rituximab, control irrelevant Ab daclizumab, or saline. All
results of in vivo studies of tumor growth are presented with week 0 (t 
0) corresponding to the first rituximab treatment. All procedures with an-
imals were conducted in conformity with the institutional guidelines that
are in compliance with national and international laws and policies.
Depletion of complement in vivo
To test the role of complement, groups of mice were treated with 25 U of
cobra venom factor (CVF)3 from Quidel or PBS only on days1, 2, 4, and
8 with respect to the first rituximab treatment in the BJAB model.
Depletion of NK cells, polymorphonuclear (PMN) cells, and
macrophages in vivo
In experiments to test the role of NK and neutrophils, groups of CD-1
nu/nuBR mice were used. Mice were i.p. inoculated twice a week with the
anti-NK cell Ab TM-1 recognizing the murine IL-2R -chain (32) and
with anti-GR1 Ab RB6-8C5 specific for murine neutrophils (33), starting
2 days before rituximab inoculation, as previously described (11). In some
experiments, Rag2 and cytokine receptor common  chain double knock-
out mice (Rag2/c/) in a C57BL background lacking T and B lym-
phocytes as well as NK cells were used (Taconic Farms). These mice were
s.c. inoculated with BJAB cells and treated with the standard doses of
rituximab as described for athymic mice. To test the role of macrophages,
groups of mice were treated i.p. with three injections of 150, 60, and 60 l
of clodronate-liposomes or PBS-liposomes on days 1, 6, and 13, respec-
tively, relative to the first rituximab administration (34), as previously de-
scribed (13). This procedure has been shown to deplete phagocytic mac-
rophages from spleen, liver, and lymph nodes (35–38). Clodronate-
liposomes and PBS-liposomes were obtained from Dr. N. van Rooijen
(Vrije Univeriteit, Amsterdam, The Netherlands) and were prepared as
described previously (39).
CCL3 antagonist synthesis and treatment
The CCL3 antagonist was synthesized following the sequence of aa 11–70
of human CCL3 and was named CCL3(11–70). It was synthesized by
step-wise solid phase methods using tBoc protection chemistry. After hy-
drogen fluoride deprotection, the polypeptides were folded and purified by
a minimum of two rounds reverse phase HPLC. Purity of the products was
assessed by ion-exchange HPLC and mass spectrometry. The measured
mass of the final product as determined by electrospray mass spectrometry
was consistent with the average mass calculated from the atomic compo-
sition. The final product in PBS was stored at 80°C in aliquots for single
use. For in vivo assays, groups of mice were inoculated with the standard
10  106 BJAB cells in each flank. After 16–20 days when tumors started
to become palpable, which is 1 wk before the first rituximab treatment (t
week 1), antagonist treatment was initiated, giving 125 g of CCL3
antagonist (aa 11–70) i.p. every 2 days for a total of eight treatments. After
four antagonist treatments (t 0), the standard dose of rituximab or control
saline was i.p. administered. Antagonist treatment was maintained up to
day 7 with respect to the first rituximab inoculation (t  week 1).
Rituximab was given on a weekly basis for a total of three inoculations
and tumor growth was recorded every 2 days.
Chemotaxis assays
CD14 monocytes were purified from PBMC from normal volunteers by
positive selection using anti-CD14 microbeads (Miltenyi Biotec). Cell mi-
gration was assayed by standard chemotaxis assays using 48-well modified
Boyden chamber (NeuroProbe) and 5-m pore-size polyvinylpyrrolidine-
free polycarbonate filter membranes (NeuroProbe). Different dilutions of
CCL3 agonist (R&D Systems), CCL3(11–70) antagonist, BJAB superna-
tant, or rituximab alone were added in duplicate wells to the lower cham-
ber, and 5 104 CD14 cells/well were added to the upper chamber in the
presence or absence of antagonist. Chemotaxis was measured by cell count
of stained filters collected after 1 h incubation at 37°C. Filters were stained
with Diff-Quik solutions (Dade Behring Spa), and 5 unit fields per filter
were counted at 50 magnification using a Zeiss microscope. Migration
index is defined as the mean number of migrated cells in treated samples
divided by cells migrated in medium only.
Detection of CCL3 and CCL4 proteins
For detection of chemokine secretion in vitro, BJAB cells were plated in
the presence or absence of 10 g/ml rituximab. After 24 h at 37°C, su-
pernatants were collected and analyzed for CCL3 and CCL4 content using
colorimetric ELISA kits (Endogen). For detection of CCL3 induction in
vivo, 10  106 BJAB cells were s.c. inoculated in CD-1 nu/nuBR mice as
described. When the tumor reached 200 mm2, 250 g of rituximab or
saline was i.v. administered to different mice. After 4 h, mice were sacri-
ficed and tumors were collected, fixed in formalin, and embedded in par-
affin. CCL3 in tumor tissue was detected by standard immunohistochem-
istry using goat anti-human CCL3 Ab and the HRP-DAB system (R&D
Systems).
Statistical analyses
Statistical analyses between different experimental groups were per-
formed using the Student’s t test. Statistical significance was set at a
value of p  0.05.
Results
Rituximab induces CCL3/4 mRNA and protein expression in
lymphoma lines and freshly isolated samples
We have previously shown by gene chip analysis that rituximab
induces CCL3 and CCL4 mRNA expression 2- to 10-fold in the
BJAB as well as other B lymphoma cell lines in vitro (16). No
other chemokine was found to be up- or down-regulated in the
gene chip analysis (16). We further wanted to verify the specificity
of CCL3/4 induction. BJAB cells were stimulated for 4 h in the
presence or absence of 10 g/ml rituximab, the humanized IgG1
anti-CD52 Ab alemtuzumab, or mouse mAbs against CD22,
CD23, and CD37 molecules that are all expressed on BJAB cells
3 Abbreviations used in this paper: CVF, cobra venom factor; PMN,
polymorphonuclear.
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(data not shown). CCL3 and CCL4 mRNA expression was then
analyzed by quantitative PCR. As shown in Fig. 1A, CCL3 and
CCL4 were specifically induced by rituximab but not by any of the
other mAbs, with an 8- and 3-fold increase over controls, respec-
tively ( p  0.001), whereas other Abs were inactive. CCL3 and
CCL4 were also induced ( p  0.001) by the F(ab)2 of rituximab,
indicating that induction did not require the Fc portion of the Ab
(Fig. 1A). The kinetics of CCL3 and CCL4 induction in vitro were
also analyzed at 4, 24, and 48 h. Both -chemokines showed a
peak mRNA induction at 4 h that gradually decreased at 24 and
48 h (Fig. 1B). CCL3/4 mRNA expression was studied in five
other lymphoma cells lines. Rituximab induced CCL3 and CCL4
expression in three of the five cell lines, by 2- to 30-fold and 2- to
3-fold, respectively (data not shown) (16).
We next determined whether up-regulation of the mRNA was
accompanied by induction of the proteins. BJAB cells were incu-
bated in the presence or absence of rituximab, and supernatant was
collected after 24 h and analyzed for CCL3 and CCL4 by ELISA.
As shown in Fig. 1C, rituximab induced a 20-fold increase in
CCL3 and CCL4 protein secreted by BJAB cells, which reached 4
and 1 ng/ml in the supernatant, respectively. As expected the ir-
relevant Ab daclizumab had no effect on CCL3 protein expression
(data not shown). Furthermore, no induction of CCL22 or IL-8
tested as controls was detected (data not shown). To further de-
termine whether CCL3 and CCL4 induction also takes place in
freshly isolated neoplastic B cells, cells from three patients (two
patients with Burkitt’s lymphoma and one ALL-L3 leukemia pa-
tient) were incubated with rituximab or control Ab, and CCL3/
CCL4 was measured in the supernatant after 24 h. As shown in
Fig. 1C, rituximab induced CCL3 in two of three patients, while
CCL4 was induced in one patient.
Because the CCL3 protein was generally more highly expressed
in vitro than CCL4, we investigated whether the CCL3 protein
induction could also take place in vivo. For this purpose, irradiated
athymic mice were s.c. inoculated with 10 106 BJAB cells. After
the tumor had reached 250 mm2 (3–4 wk after inoculum), ani-
mals were treated with 250 g of rituximab or with saline only.
Animals were sacrificed and tumors excised and fixed for analysis
of CCL3 protein expression by immunohistochemistry. As shown
in Fig. 2A, increased CCL3 protein expression was detected 4 h
after rituximab inoculation. Staining was specific as shown by in-
cubation with secondary Ab only (Fig. 2A). Similar results were
obtained at 16 h (data not shown).
We conclude that rituximab binding to CD20 specifically in-
duces CCL3 and CCL4 mRNA and protein expression in several B
lymphoma cells, and that this mechanism also takes place in vivo.
Rituximab treatment in vivo eradicates the BJAB tumor in a
complement-dependent manner
To further characterize the BJAB s.c. model, we next investigated
the therapeutic activity of rituximab in this context. Groups of
mice were inoculated with BJAB cells and, after the tumor had
developed to 250 mm2, a weekly 250-g rituximab treatment
was started (day 0). Tumor size was recorded weekly for 3 wk. As
shown in Fig. 2B, rituximab treatment eradicated the tumor within
about 3 wk. This effect was highly reproducible ( p  0.0001) and
was not observed with the control irrelevant Ab daclizumab (see
below and data not shown).
Because previous syngeneic models in fully immunocompetent
animals (11, 13), as well as xenograft models in SCID mice (12),
had suggested that complement is required for the therapeutic ac-
tivity of rituximab, we next verified this hypothesis in our estab-
lished BJAB s.c. model. Tumor inoculated animals were treated
with CVF on days 1, 2, 4, and 8 (Fig. 2C, filled arrows), with
respect to the first rituximab treatment. Longer treatment was not
possible because CVF is antigenic. As shown in Fig. 2C, CVF
reduced rituximab efficacy dramatically ( p  0.0001) during the
first, second, and to some extent third Ab infusion (Fig. 2C, open
arrows). As expected, the effect was reversible and, upon contin-
ued rituximab administration in animals previously treated with
CVF, the tumor mass started to decrease significantly after the
fourth rituximab administration in this group of mice (Fig. 2C).
We conclude that rituximab is a very effective therapeutic agent in
the established BJAB s.c. model and that complement is required
for this activity.
N-terminally truncated CCL3(11–70) has antagonist activity
To be able to investigate the role of CCL3/4 in the mechanism of
action of rituximab in vivo, we looked for an antagonist of these
proteins. CCL3 and CCL4 are highly homologous chemokines that
share the CCR1 and CCR5 receptors. The N-terminal amino acids
of several -chemokines are known to be important for receptor
FIGURE 1. Rituximab up-regulates CCL3/4 mRNA
and protein expression in vitro and in vivo. A, Exponen-
tially growing BJAB cells were plated in the presence of
10 g/ml rituximab (ritux), its F(ab)2, anti-CD52
(alem), anti-CD25 (dacliz), or murine anti-CD22, anti-
CD23, or anti-CD37 Abs. Total RNA was extracted af-
ter 4 h. Fold induction over control of CCL3 (o) and
CCL4 (f) mRNA was determined by real-time PCR.
The results are representative of two independent exper-
iments. B, BJAB cells were plated in the presence of 10
g/ml rituximab or control daclizumab Ab, and RNA
was extracted after 1, 4, 24, or 48 h. Fold induction of
the CCL3 (Œ) and CCL4 (‚) over control cells was
determined by real-time PCR. The results are represen-
tative of two independent experiments. C, Cells from the
BJAB cell lines from two Burkitt’s lymphoma patients
(pt1 and pt2) and one ALL-L3 patient (pt3) were plated
in the presence of 10 g/ml rituximab (Rit) or control
daclizumab (Ctrl) Ab, and supernatants were collected
at 24 h. Amounts of CCL3 and CCL4 proteins in the
supernatant was determined by ELISA. Results are the
mean and SD of triplicate wells. , p  0.05; , p 
0.001; , p  0.0001.
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activation, N-terminal truncations, or modifications resulting in an-
tagonist proteins (reviewed in Ref. 17). We have therefore pro-
duced and purified a N-terminally truncated CCL3 peptide encod-
ing aa 11–70 of the full-length protein and obtained a molecule
that competed for CCL3 binding in vitro (data not shown). The
antagonistic properties of the CCL3(11–70) molecule were then
analyzed in chemotactic assays in vitro. Recombinant wild-type
CCL3 induced migration of purified monocytes with maximal ac-
tivity at 50–100 ng/ml (Fig. 3A). In contrast, CCL3(11–70) was
inactive in chemotactic assays, when tested up to 200 ng/ml (Fig.
3A and data not shown). We then measured the capacity of the
antagonist peptide to inhibit CCL3-mediated migration of mono-
cytes. As shown in Fig. 3B, cells incubated in the presence of
CCL3(11–70) failed to migrate to optimal concentrations of CCL3
(100 ng/ml; p  0.05). These data demonstrate that the truncated
CCL3(11–70) peptide has antagonist activity for CCL3 in vitro.
Because BJAB cells secrete CCL3 following incubation with
rituximab, we also investigated whether the CCL3 antagonist was
able to inhibit migration of cells induced by BJAB supernatant. As
shown in Fig. 3C, monocytes migrated in response to BJAB su-
pernatant collected 24 h after rituximab treatment ( p  0.05), but
they did not migrate significantly to supernatant from either un-
stimulated cells or cells stimulated with rituximab alone. Further-
more, monocyte migration to stimulated BJAB supernatant was
blocked by CCL3(11–70) to a similar extent as that to recombinant
CCL3 ( p  0.05). These data suggest that rituximab binding to
BJAB can induce secretion of functionally active CCL3 that can be
inhibited by the antagonist.
FIGURE 2. Rituximab activity in the established BJAB B lymphoma
model in vivo. A, A total of 10  106 BJAB cells were s.c. inoculated in
irradiated athymic mice. After the tumors had developed, the mice were
treated with 250 g of rituximab i.p., mice were sacrificed, and tumor
tissue collected and fixed at 4 h. Tissue sections were stained with anti-
human CCL3 Ab or secondary anti-goat Ab as control. Original magnifi-
cation is 20. The results represent two independent experiments. B, A
total of 10  106 BJAB cells were inoculated as in A. After the tumors had
developed to 250 mm2, the mice were treated weekly i.p. with either 250
g of rituximab (Rit) (f) or saline (Ctrl) () once a week, and tumor
growth measured once a week (n  5 mice per group). C, Mice were
inoculated as in B. When tumor developed, groups of mice (n  5) were
treated with CVF (days 1, 2, 4, and 8) (triangles) or PBS only (squares)
and 1 day later with weekly injections of 250 g of rituximab (closed
symbols) or saline only (open symbols), with tumor growth recorded once
a week. Arrows indicate the timing of the different treatments. Data are
representative of at least two experiments.
FIGURE 3. CCL3(11–70) is an antagonist of CCL3 in vitro. A, The
migration of CD14 monocytes in response to 1–100 ng/ml CCL3 or
CCL3(11–70) antagonist was measured in chemotaxic assays. Results are
the mean and SD of three independent experiments. B, The effect of
incubating the target cells with 100 ng/ml CCL3(11–70) antagonist on the
migration of CD14 cells to 100 ng/ml CCL3 was determined. Results are
the mean and SD of two independent experiments. C, BJAB cells were
unstimulated or stimulated with rituximab (10 g/ml), and supernatant
(SN) collected after 24 h culture. Monocytes were then tested in chemo-
taxis assays against these supernatants (culture medium), rituximab alone,
or CCL3 (50 ng/ml) in the presence or absence of CCL3(11–70) antagonist
(50 ng/ml). , p  0.05.
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The antagonist CCL3(11–70) inhibits the therapeutic activity of
rituximab in the BJAB tumor model
We next investigated the role of CCL3 in vivo in the mechanism
of action of rituximab, using the BJAB tumor model and
CCL3(11–70) antagonist. We first evaluated whether antagonist
treatment affected tumor growth in absence of rituximab. For this
purpose, 10 mice were inoculated with the standard dose of BJAB.
When tumor growth started to become palpable (after 16–20
days), half the animals were i.p. treated with 125 g of CCL3(11–
70) antagonist every 2 days, and tumor growth was measured. The
growth curve of the tumor was the same in the presence or absence
of antagonist treatment (Fig. 4). We then determined the effect of
antagonist on the therapeutic activity of rituximab. Again animals
were inoculated with BJAB cells and after 16 days (when tumors
became palpable and corresponding to week 1 relative to ritux-
imab treatment), half of the animals were i.p. treated every 2 days
with either 125 g of CCL3(11–70) antagonist or control saline.
One week later (week 0), when the tumor size had reached nearly
200 mm2, groups of five antagonist-treated and control animals
were given the standard dose of rituximab. Antagonist treatment
was continued further for 1 wk after initiating rituximab and was
stopped at week 1 (Fig. 4, gray bar). In contrast, rituximab treat-
ment was continued with two other infusions on weeks 1 and 2
(Fig. 4, open arrows). Tumor growth in all animals was registered
every 2 days throughout the experiment. The results confirmed that
antagonist treatment did not affect tumor growth in the absence of
rituximab treatment because tumor growth curves for all animal
groups were superimposable up to week 0 (the beginning of rit-
uximab treatment). In contrast, repeated inoculation with
CCL3(11–70) completely abolished the therapeutic activity of rit-
uximab. Indeed, although control animals treated with rituximab
and mock saline showed rapid tumor disappearance, already com-
plete 7–10 days following rituximab inoculation, the antagonist-
treated animals did not respond to rituximab treatment but showed
continued tumor growth during the same time period (week 0 to 1),
overlapping with that of untreated mice (Fig. 4). Study of growth
curves at later time points, i.e., after antagonist treatment had been
interrupted, demonstrated that the inhibition by CCL3(11–70) of
the therapeutic activity of rituximab is reversible. Indeed the sec-
ond and third rituximab inoculations, performed after antagonist
treatment were stopped, led to gradual reduction of the tumor mass
over the following 2-wk period. Altogether these data demonstrate
that CCL3(11–70) antagonist treatment dramatically inhibits the
therapeutic activity of rituximab in vivo and that the effect is
reversible.
The therapeutic activity of rituximab also requires immune cells
for tumor eradication
The inhibitory effects of CCL3(11–70) antagonist on the therapeu-
tic activity of rituximab suggested that -chemokines, either up-
regulated directly by rituximab or induced during the inflammatory
reaction triggered by the Ab, recruit and/or activate immune ef-
fector cells that then eradicate the tumor. To identify the immune
effector cells involved in lymphoma control following rituximab
inoculation, we analyzed the effect of depleting different leukocyte
populations in vivo. NK cells or neutrophils were depleted by re-
peated treatment with the TM-1 and RB6-8C5 Abs, respectively,
starting 2 days before rituximab treatment, as previously described
(11). As shown in Fig. 5, A and B, depletion of either NK cells or
PMN cells did not affect tumor growth in absence of rituximab but
essentially abolished the therapeutic activity of the Ab ( p 
0.0001). To verify that the loss of rituximab activity was not an
artifact due to the repeated treatments with anti-NK Abs, we also
tested the role of NK cells by using Rag2/c/ mice, which
completely lack NK cells as well as lymphocytes. These mice were
s.c. inoculated with the standard doses of BJAB cells and were
FIGURE 4. The CCL3(11–70) antagonist abolishes the therapeutic ac-
tivity of rituximab in a reversible manner. A total of 10  106 BJAB cells
were s.c. inoculated in irradiated athymic mice. After tumor became pal-
pable, two groups (n  5 mice) were repeatedly treated every 2 days with
125 g of CCL3(11–70) antagonist (triangles) (week 1 with respect to
rituximab treatment) or saline only (squares). One week later (week 0),
standard treatment i.p. with 250 g of rituximab (open symbols) or saline
only (closed symbols) was initiated. The last antagonist treatment was ad-
ministered at week 1 together with the second rituximab injection. A third
rituximab inoculation was given on week 2. Tumor growth was measured
every 2 days. The gray box (antagonist) indicates the duration of antagonist
treatment and arrows represent the timing of rituximab administration. Re-
sults are representative of two independent experiments.
FIGURE 5. Immune cells are required for the therapeutic activity of
rituximab in the BJAB lymphoma model. Athymic irradiated mice were
inoculated s.c. with 10  106 BJAB cells. When the tumors reached 250
mm2, groups (n  5 mice) were repeatedly treated with anti-NK Ab (A),
anti-PMN Ab (B), or clodronate-liposomes (M) (D) (triangles) or with
saline (Ctrl) (squares) followed by weekly rituximab (closed symbols) or
saline only (open symbols). C, Rag2/c/ mice were s.c. inoculated
with 10  106 BJAB and then treated with the standard rituximab weekly
schedule (closed symbols) or saline only (open symbols). Tumor growth
was recorded weekly. All results are representative of two experiments.
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then treated with rituximab as before. As shown in Fig. 5C, ritux-
imab was completely inactive in the double knockout mice, con-
firming the requirement for NK cells by an independent method.
The CCL3 receptors CCR5 and CCR1 are also expressed by
macrophages (40). We therefore also analyzed the role of macro-
phages by repeated treatments with clodronate-liposomes or PBS-
liposomes as control, starting 2 days before rituximab treatment.
As shown in Fig. 5D, depletion of macrophages also led to loss of
the therapeutic activity of rituximab.
The data presented demonstrate that different immune effector
cells are required to eradicate the bulky BJAB tumor following
complement activation and CCL3/4 induction. We therefore also
investigated whether CCL3(11–70) antagonist treatment modified
immune cell infiltration into the tumor, either in the presence or
absence of rituximab treatment. For this purpose, antagonist- or
rituximab-treated or control animals were sacrificed at different
times after the first rituximab treatment, and infiltration of NK
cells, PMN cells, and macrophages within the tumor were ana-
lyzed by immunohistochemistry using the TM-1, RB6-8C5, and
F480 Abs, respectively. Cellular infiltration was quantified by
semi-automated counting of stained cells. Infiltration of tumor with
NK cells, macrophages, and PMN cells could be observed by im-
munohistochemistry in untreated tumors. In two separate experi-
ments, rituximab treatment did not induce a reproducible increase
in immune cell infiltrate in the tumor 4, 8, 24, 48, or 72 h after
treatment. Macrophages were particularly abundant in the tumor
and could not be observed to increase or decrease. PMN and NK
cells were also clearly infiltrating the tumor even in the absence of
Ab treatment, but again, their overall number was not reproducibly
modified after rituximab inoculation (data not shown). Simi-
larly we could not detect a reproducible and quantitative effect of
antagonist treatment on tumor cell infiltration either in rituximab-
treated or untreated animals at 8 or 24 h after the first rituximab treat-
ment, for any of the populations analyzed (data not shown). These
data suggest that the dramatic effects of both rituximab and
CCL3(11–70) antagonist occur without macroscopic differences in
immune cell recruitment within the tumor, at least within the time
period examined.
Discussion
In this article, we demonstrate that rituximab induces CCL3 and
CCL4 mRNA and protein expression in lymphoma cells in vitro
and in vivo and suggest that the CCL3 family of chemokines are
involved in the therapeutic activity of rituximab. Induction of
CCL3 and CCL4 in BJAB cells in vitro was demonstrated both at
the RNA and protein level, and chemokines produced were shown
to be functional in chemotaxis assays. CCL3/4 induction was spe-
cific, and the F(ab)2 of rituximab also up-regulated CCL3/4 sug-
gesting that signaling through the CD20 molecule and not FcR
was responsible for chemokine induction. CCL3 RNA and protein
were more highly expressed in BJAB cells than CCL4, and was
demonstrated in vivo. We have previously shown by microarray
analysis that a very restricted set of genes are up-regulated by
CD20-mediated signaling in B lymphoma cells (16). Indeed other
chemokines analyzed were not modulated by rituximab. Study of
other B lymphoma lines showed that rituximab induced CCL3/4 in
four of six lymphoma lines studied (data not shown) (16). For
example CCL3 mRNA was induced 20-fold in EsIII cells but was
not up-regulated in DHL-4 or Raji cells (16). Similarly, we have
shown that CCL3/4 protein induction can be observed in some but
not all freshly isolated lymphoma/leukemia samples (2/3). These
results therefore demonstrate a heterogeneity of CCL3/4 induction
also in naturally occurring human lymphomas. Whether such het-
erogeneity has an impact on the response of patients to rituximab
in vivo is an intriguing hypothesis that deserves to be further
investigated.
To further study the role of CCL3/4 in vivo, we set up and
characterized a s.c. xenograft lymphoma model in athymic mice
using BJAB cells. In this model, rituximab was able to eradicate
the tumor within 2–3 wk, even though the BJAB lymphoma was
relatively bulky because it was allowed to grow for 3–4 wk until
it reached 200–250 mm2 before Ab treatment. Cured animals
could be further kept for 3 mo without showing recurrence of
tumor. CVF treatment of BJAB-inoculated animals suggested that
complement is at least in part required for the therapeutic activity
of rituximab also in this model, in agreement with our previous
reports and reports from other groups using either CVF (12, 13) or
C1q/ animals (11). Also in human models, current evidence
suggests that complement activation is an early event following
rituximab administration to lymphoma patients, detected by the
rapid release of C3, C4, and C5 complement fragments, which
precedes cytokine release (41, 42). Other reports suggest that the
cellular microenvironment may determine the extent of comple-
ment dependency of B cell clearance in mice (10).
To study the role of CCL3 in this model, we have synthesized
and functionally characterized CCL3 antagonist CCL3(11–70),
composed of the wild-type protein truncated at the N terminus.
CCL3(11–70) showed no chemotactic activity in vitro but inhib-
ited CCL3-induced chemotaxis. Several analogs of the -chemo-
kine family with modified or truncated N-termini have been de-
scribed to have antagonist activity for the parent chemokine in
vitro and in vivo (17, 43–45). These data therefore suggest that for
CCL3, the N terminus also has an important role for receptor sig-
naling. Most interestingly, the CCL3(11–70) antagonist showed a
dramatic effect on the therapeutic activity of rituximab in vivo in
the BJAB xenograft model. Although CCL3(11–70) had no effect
on tumor growth in the absence of rituximab, it completely abol-
ished the capacity of the Ab to eradicate the lymphoma. This effect
was reversible because interruption of antagonist treatment was
able to restore the therapeutic activity of the Ab. We reasoned that
such a dramatic effect of antagonist treatment was likely due to
interference with the recruitment and/or activation of immune cells
required to kill tumor cells following rituximab administration.
Indeed antagonist was able to inhibit the migration of monocytes
in response to rituximab-stimulated BJAB supernatant in vitro. In
vivo, depletion of different immune cell populations, including NK
cells, polymorphonuclear cells, and macrophages, demonstrated
that these cells are required for tumor eradication by rituximab.
The role of NK cells was confirmed using Rag2/c/ animals
that completely lack NK cells, and in which rituximab was indeed
inactive. Thus CCL3 is likely to act through activation/recruitment
of immune cells. A role for the macrophage phagocyte network has
also been described by others using mouse anti-CD20 mAbs (46).
In this latter case, however, complement did not seem to be re-
quired. These differences may be due to the different Abs used, and
perhaps to the bulk of tumor cells in our study. Interestingly
Hamaguchi et al. (46) observed improved peritoneal cavity B cell
depletion after inflammation elicited effector cell migration into
this body location. In the bulky BJAB tumor model described in
this study, different immune cell populations cooperate with each
other in eradicating the tumor. A similar combined activity of dif-
ferent mechanisms and different effector cells in the mechanism of
action of rituximab has also been described by others (8, 10). Fur-
thermore, the cooperation with immune cells, complement, and in-
flammatory mediators suggested in this study is reminiscent of that
observed in Ab-mediated autoimmune diseases (47). A synergistic
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effect of different immune cell types could also be explained by in-
duction of inflammatory cytokine/chemokine cascades functionally
linking the different immune cells (21, 28, 48).
In view of the evidence for a role of immune cells in the ther-
apeutic activity of rituximab in this model, we also investigated
whether rituximab or CCL3 antagonist modified the infiltration of
these cells in the tumor. We could not detect any significant and
reproducible effect of rituximab on infiltration by macrophages,
NK cells, or neutrophils at 4–72 h after Ab administration. This
result may have been due to the fact that these cells were already
present in the lymphoma in significant numbers in the absence of
rituximab treatment. Similarly, antagonist treatment did not mod-
ify reproducibly the number of infiltrating cells. We hypothesize
therefore that rituximab and antagonist may affect the activation of
immune cells, the cross-talks between different cell types, or their
fine movements within the tumor rather their actual macroscopic
recruitment within the tissue (20). It is worth noting that the in-
flammatory response to rituximab triggered by complement acti-
vation and its interaction with FcR on immune cells is likely to
induce production of CCL3 and other inflammatory CC chemo-
kines by immune cells within the tumor, in particular infiltrating
macrophages, as already demonstrated in different models of im-
mune complex-mediated tissue injury (49–51). Furthermore, the
two major receptors for CCL3 are CCR1 and CCR5, which also
bind other molecules of the -chemokine family, including CCL4,
CCL5 (RANTES), as well as other molecules (44, 52, 53). Thus
the CCL3(11–70) antagonist is likely to inhibit the activity of sev-
eral chemokines in vivo, produced both by tumor and immune-
infiltrating cells. This hypothesis together with a better definition
of the role of CCR1 and CCR5 in the therapeutic activity of rit-
uximab in vivo should be further investigated and is beyond the
scope of this article.
Evidence for an important antitumor activity of CCL3 as well as
other chemokines has been presented previously (reviewed in Ref.
54) in different in vivo tumor models (20–23, 55–58). However
these reports mostly involve exogenous chemokines overexpressed
through their direct inoculation or through gene transfer into the
tumor cells. In the BJAB model presented in this study in contrast,
we have shown a fundamental role for endogenously expressed
chemokine. Furthermore, in contrast with some of these reports,
CCL3 antagonist inhibited the therapeutic activity of rituximab but
had no effect on spontaneous tumor growth in the absence of Ab
treatment. Thus the antagonist effect was specific for the response
to rituximab treatment. This observation is similar to some other
published results showing antitumor effects of chemokines only in
combination with other factors, such as drug-induced tumor de-
struction or coadministered cytokines (21, 54).
The data presented suggest that in this rather bulky BJAB tumor
model, the combination of different immune-mediated mecha-
nisms is necessary for tumor control. This suggestion may not be
so surprising given the known interplay between complement ac-
tivation, inflammation, and immune cells (15, 59). Indeed ritux-
imab binding to its target triggers rapid complement activation that
initiates a cascade of events that includes release of proinflamma-
tory factors, C3a and C5a (41, 42). Secondly rituximab binding to
CD20 induces CCL3 and CCL4 expression by lymphoma cells as
shown in this study. These may contribute to immune effector cell
activation. Finally, rituximab signaling through FcR may also
lead to release of proinflammatory cytokines such as TNF- and
IL-6, as described by other reports (41, 60), which may further
amplify the immune response (61, 62) for optimal tumor removal
by phagocytosis or Ab-dependent cytotoxicity. This network, in
addition to inducing maximal immune function, may also create
interdependency of different immune cell types, leading to the ob-
served need for all cell types for the effective eradication of tumor.
These data altogether suggest that individual differences in ex-
pression of the -chemokine family of proteins, either by the tu-
mor itself or by infiltrating immune cells, may play a role in the
clinical response of different patients to rituximab. Interestingly
CCL3 was not expressed or induced in Raji cells, and rituximab
was less active against the Raji than BJAB s.c. tumor (E. Cittera,
unpublished observation). Also, differences in expression of CCL3
in human lymphomas have been described that in part predict pa-
tients’ prognosis (63). Recently a genetic variation in the copy
number of the homologous human genes CCL3-L1 and CCL4-L1
has been described that leads to variable protein expression levels
(64). Further investigation of the role of CCL3 in the response of
lymphoma patients to rituximab is therefore warranted.
In summary, this study shows rituximab induces the CCL3 and
CCL4 -chemokines in B lymphoma cells. Furthermore, it dem-
onstrates that -chemokines and complement are required for the
therapeutic activity of rituximab in a bulky lymphoma xenograft
model, and may cooperate in the recruitment/activation of the in-
nate immunity network.
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